Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 154

1.

Fibrinogen, mortality and incident cardiovascular complications in end-stage renal failure.

Zoccali C, Mallamaci F, Tripepi G, Cutrupi S, Parlongo S, Malatino LS, Bonanno G, Rapisarda F, Fatuzzo P, Seminara G, Stancanelli B, Nicocia G, Buemi M.

J Intern Med. 2003 Aug;254(2):132-9.

2.

Homocysteine as a risk factor for cardiovascular disease in patients treated by dialysis: a meta-analysis.

Heinz J, Kropf S, Luley C, Dierkes J.

Am J Kidney Dis. 2009 Sep;54(3):478-89. doi: 10.1053/j.ajkd.2009.01.266. Epub 2009 Apr 8.

PMID:
19359080
3.

Plasma homocysteine levels and cardiovascular mortality in patients with end-stage renal disease.

Buccianti G, Baragetti I, Bamonti F, Furiani S, Dorighet V, Patrosso C.

J Nephrol. 2004 May-Jun;17(3):405-10.

PMID:
15365961
4.

Chronic inflammation and mortality in haemodialysis: effect of different renal replacement therapies. Results from the RISCAVID study.

Panichi V, Rizza GM, Paoletti S, Bigazzi R, Aloisi M, Barsotti G, Rindi P, Donati G, Antonelli A, Panicucci E, Tripepi G, Tetta C, Palla R; RISCAVID Study Group.

Nephrol Dial Transplant. 2008 Jul;23(7):2337-43. doi: 10.1093/ndt/gfm951. Epub 2008 Feb 27.

PMID:
18305316
5.

Advanced oxidation protein products as risk factors for atherosclerotic cardiovascular events in nondiabetic predialysis patients.

Descamps-Latscha B, Witko-Sarsat V, Nguyen-Khoa T, Nguyen AT, Gausson V, Mothu N, London GM, Jungers P.

Am J Kidney Dis. 2005 Jan;45(1):39-47.

PMID:
15696442
6.

Predictors for cardiovascular morbidity and overall mortality in Tunisian ESRD patients: a six year prospective study.

Fellah H, Hammami MB, Feki M, Boubaker K, Abdallah TB, Lacour B, Mebazaa A, Kaabachi N.

Clin Biochem. 2009 May;42(7-8):648-53. doi: 10.1016/j.clinbiochem.2008.12.023. Epub 2009 Jan 8.

PMID:
19166827
7.

Circulating E-selectin as a risk marker in patients with end-stage renal disease.

Malatino LS, Stancanelli B, Cataliotti A, Bellanuova I, Fatuzzo P, Rapisarda F, Leonardis D, Tripepi G, Mallamaci F, Zoccali C.

J Intern Med. 2007 Oct;262(4):479-87.

8.

Positive correlation of CRP and fibrinogen levels as cardiovascular risk factors in early stage of continuous ambulatory peritoneal dialysis patients.

Tekin IO, Pocan B, Borazan A, Ucar E, Kuvandik G, Ilikhan S, Demircan N, Ozer C, Kadayifci S.

Ren Fail. 2008;30(2):219-25. doi: 10.1080/08860220701813350.

PMID:
18300125
9.

Serum albumin, C-reactive protein, interleukin 6, and fetuin a as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD.

Honda H, Qureshi AR, Heimbürger O, Barany P, Wang K, Pecoits-Filho R, Stenvinkel P, Lindholm B.

Am J Kidney Dis. 2006 Jan;47(1):139-48.

PMID:
16377395
10.

Soluble CD154 is a unique predictor of nonfatal and fatal atherothrombotic events in patients who have end-stage renal disease and are on hemodialysis.

Hocher B, Liefeldt L, Quaschning T, Kalk P, Ziebig R, Godes M, Relle K, Asmus G, Stasch JP.

J Am Soc Nephrol. 2007 Apr;18(4):1323-30. Epub 2007 Feb 21.

11.

Additive value of immunoassay-measured fibrinogen and high-sensitivity C-reactive protein levels for predicting incident cardiovascular events.

Mora S, Rifai N, Buring JE, Ridker PM.

Circulation. 2006 Aug 1;114(5):381-7. Epub 2006 Jul 24.

PMID:
16864722
12.

Prognostic value of troponin T and homocysteine in patients with end-stage renal disease.

Sahinarslan A, Güz G, Okyay K, Mutluay R, Yalçin R, Bali M, Sindel S, Cengel A.

Turk Kardiyol Dern Ars. 2008 Sep;36(6):382-7.

13.

Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease.

Zoccali C, Mallamaci F, Tripepi G, Benedetto FA, Cutrupi S, Parlongo S, Malatino LS, Bonanno G, Seminara G, Rapisarda F, Fatuzzo P, Buemi M, Nicocia G, Tanaka S, Ouchi N, Kihara S, Funahashi T, Matsuzawa Y.

J Am Soc Nephrol. 2002 Jan;13(1):134-41.

14.

Cardiovascular mortality and C-reactive protein in elderly patients beginning dialysis: reverse epidemiology?

Millet C, Bosson JL, Pernod G, Wauters JP, Couturier P, Quesada JL, Zaoui P.

Aging Clin Exp Res. 2011 Oct-Dec;23(5-6):357-63.

PMID:
22526070
15.

Abdominal obesity and all-cause and cardiovascular mortality in end-stage renal disease.

Postorino M, Marino C, Tripepi G, Zoccali C; CREDIT (Calabria Registry of Dialysis and Transplantation) Working Group.

J Am Coll Cardiol. 2009 Apr 14;53(15):1265-72. doi: 10.1016/j.jacc.2008.12.040.

16.

Soluble Fas: a novel predictor of atherosclerosis in dialysis patients.

Troyanov S, Hébert MJ, Masse M, Vigneault N, Sirois I, Madore F.

Am J Kidney Dis. 2003 May;41(5):1043-51.

PMID:
12722039
17.

Interleukin-8 is a powerful prognostic predictor of all-cause and cardiovascular mortality in dialytic patients.

Panichi V, Taccola D, Rizza GM, Consani C, Ghiadoni L, Filippi C, Cristofani R, Panicucci E, Migliori M, Sidoti A, Biagioli M, Boracelli D, Barsotti G, Tetta C.

Nephron Clin Pract. 2006;102(2):c51-8. Epub 2005 Oct 13.

PMID:
16224196
18.

The effect of single and repeatedly high concentrations of C-reactive protein on cardiovascular and non-cardiovascular mortality in patients starting with dialysis.

den Elzen WP, van Manen JG, Boeschoten EW, Krediet RT, Dekker FW.

Nephrol Dial Transplant. 2006 Jun;21(6):1588-95. Epub 2006 Jan 31.

PMID:
16449284
19.

N-terminal pro-brain natriuretic peptide: an independent risk predictor of cardiovascular congestion, mortality, and adverse cardiovascular outcomes in chronic peritoneal dialysis patients.

Wang AY, Lam CW, Yu CM, Wang M, Chan IH, Zhang Y, Lui SF, Sanderson JE.

J Am Soc Nephrol. 2007 Jan;18(1):321-30. Epub 2006 Dec 13.

20.

Plasma concentration of asymmetric dimethylarginine (ADMA) predicts cardiovascular morbidity and mortality in type 1 diabetic patients with diabetic nephropathy.

Lajer M, Tarnow L, Jorsal A, Teerlink T, Parving HH, Rossing P.

Diabetes Care. 2008 Apr;31(4):747-52. Epub 2007 Dec 27.

PMID:
18162497

Supplemental Content

Support Center